INTENSITY THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
INTENSITY THERAPEUTICS, INC. (INTS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price of $131.09 per share as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice · last filed 2026-08-11
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $131.09.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $149.11.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $150.73.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $6.15.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $131.09 10-Q · filed 2026-08-11 |
| 2026-03-31 | $149.11 10-Q · filed 2026-05-07 |
| 2025-12-31 | $150.73 10-K · filed 2026-03-27 |
| 2025-09-30 | $6.15 10-Q · filed 2025-11-06 |
| 2025-06-30 | $6.07 10-Q · filed 2025-08-07 |
| 2025-03-31 | $7.40 10-Q · filed 2025-05-13 |
| 2024-12-31 | $7.68 10-K · filed 2025-03-13 |
| 2024-09-30 | $8.24 10-Q · filed 2024-11-13 |
| 2024-06-30 | $7.58 10-Q · filed 2024-08-08 |
| 2024-03-31 | $7.62 10-Q · filed 2024-05-09 |
| 2023-12-31 | $8.15 10-K · filed 2024-03-14 |
| 2023-09-30 | $8.10 10-Q · filed 2023-11-13 |
| 2023-06-30 | $7.63 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |